Provided by Tiger Fintech (Singapore) Pte. Ltd.

First Advantage Corp.

13.62
-1.0600-7.22%
Post-market: 13.620.00000.00%16:20 EDT
Volume:2.38M
Turnover:32.69M
Market Cap:2.36B
PE:-18.35
High:14.32
Open:14.21
Low:13.45
Close:14.68
Loading ...

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

GlobeNewswire
·
03 Dec 2024

Arsenal v Man Utd tops bill in intriguing FA Cup third round draw

cityam
·
03 Dec 2024

Embattled ref ‘strongly denies’ spot-fixing claims after FA launches probe

cityam
·
27 Nov 2024

Fountain Asset Reports Decline in Financial Performance

TIPRANKS
·
27 Nov 2024

30 per cent: Football Association sets diversity target for England coaches

cityam
·
26 Nov 2024

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Business Wire
·
26 Nov 2024

Financial advisory firms gain traction, thanks to rising affluence and demand for wealth management

businesstimes
·
24 Nov 2024

BUZZ-First Advantage rises after Barclays reinstates coverage with 'overweight'

Reuters
·
21 Nov 2024

First Advantage Corp : Barclays Reinstates Coverage With Overweight Rating; Target Price $22

THOMSON REUTERS
·
20 Nov 2024

First Advantage Price Target Announced at $22.00/Share by Barclays

Dow Jones
·
20 Nov 2024

First Advantage reinstated with an Overweight at Barclays

TIPRANKS
·
20 Nov 2024

Wall Street Analysts Are Bullish on Top Industrial Goods Picks

TIPRANKS
·
20 Nov 2024

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

Benzinga
·
20 Nov 2024

Some May Be Optimistic About First Advantage's (NASDAQ:FA) Earnings

Simply Wall St.
·
19 Nov 2024

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Business Wire
·
19 Nov 2024

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

GlobeNewswire
·
18 Nov 2024

First Advantage Price Target Maintained With a $22.00/Share by RBC Capital

Dow Jones
·
16 Nov 2024

Discover US Stocks That May Be Trading Below Estimated Value In November 2024

Simply Wall St.
·
15 Nov 2024

RBC Upgrades First Advantage to Outperform, Price Target is $22

MT Newswires Live
·
15 Nov 2024

First Advantage reinstated with an Outperform at RBC Capital

TIPRANKS
·
15 Nov 2024